Psychotherapeutic Agents in End-Stage Renal Disease

Seminars in Dialysis
Rachel F EylerAloun Mary Vilay


Patients with end-stage renal disease (ESRD) are often affected by many comorbid conditions, including mental health disorders. Psychiatric illness among patients with ESRD has been associated with increased risks for nonadherence, hospitalizations, suicide, and all-cause mortality. We reviewed the pharmacokinetic data available with psychotherapeutic agents, focusing on physiologic data rather than specific dosing recommendations. Unfortunately data regarding the pharmacokinetics, efficacy, and safety of psychotherapeutic agents in ESRD remain rather limited. Of the agents available, it appears that the most data in this patient group were found with selective serotonin reuptake inhibitors and benzodiazepines. Given the small number of patients enrolled in many of the studies and the wide inter-individual variability, it was difficult to interpret the significance of results in many instances. A number of agents, such as tricyclic antidepressants, were associated with adverse effects that would be imperative to avoid in patients with ESRD. Psychotherapeutic medications should be started at low doses and titrated carefully, while monitoring the efficacy and safety of each agent.


Apr 1, 1979·Biochemical Pharmacology·A KoberI Odar-Cederlöf
Apr 1, 1977·The American Journal of Medicine·G Levy
Jul 1, 1977·Journal of Pharmaceutical Sciences·J T Slattery, G Levy
May 1, 1992·Clinical Pharmacology and Therapeutics·V D SchmithP D Kroboth
Jan 1, 1991·European Journal of Clinical Pharmacology·J SennesaelS R Bareggi
Jan 1, 1990·Fundamental & Clinical Pharmacology·C SalvadoriD Friès
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·G D DoyleB D Zussman
Jun 1, 1985·British Journal of Clinical Pharmacology·P D KrobothR P Juhl
Mar 1, 1988·Clinical Pharmacokinetics·S CacciaM Pfeffer
Dec 1, 1987·Journal of Clinical Psychopharmacology·M ShostakS Curran
Jan 1, 1987·Transactions of the Royal Society of Tropical Medicine and Hygiene·B M GreenwoodF S Oldfield
Mar 1, 1985·Clinical Pharmacology and Therapeutics·J A LiebermanJ M Kane
Jan 1, 1985·Therapeutic Drug Monitoring·J J TassetA J Pesce
Jul 9, 1966·Lancet·P A CastaldiJ H Stewart
Jul 29, 1971·The New England Journal of Medicine·M M ReidenbergF Sjöqvist
Jul 1, 1981·Clinical Pharmacology and Therapeutics·D KampfM Kessel
Nov 1, 1981·British Journal of Clinical Pharmacology·R K VerbeeckR Verberckmoes
Aug 16, 1984·Klinische Wochenschrift·H R OchsU Klehr
Jul 1, 1984·Clinical Pharmacology and Therapeutics·G R AronoffL Lemberger
Nov 1, 1983·Anesthesiology·H R VinikL R Smith
May 1, 1984·Clinical Pharmacology and Therapeutics·G MorrisonB R Walker
Jan 1, 1984·European Journal of Clinical Pharmacology·M SandozR Volmat
May 1, 1984·Artificial Organs·R D FaulknerC S Lee
Mar 1, 1982·Clinical Pharmacology and Therapeutics·S H GrossmanP A Routledge
Sep 1, 1982·Clinical Pharmacology and Therapeutics·S DawlingR Braithwaite
Jul 1, 1981·British Journal of Clinical Pharmacology·S DawlilngR Braithwaite
Dec 1, 1981·Clinical Pharmacology and Therapeutics·T G MurrayB R Walker
Jan 1, 1981·European Journal of Clinical Pharmacology·K LynnR Rosser
Jul 1, 1994·Clinical Pharmacology and Therapeutics·S M TroyR A Blum
Aug 1, 1997·Journal of Clinical Pharmacology·P H HsyuJ A Johnston
Jan 1, 1997·International Journal of Psychiatry in Medicine·M BlumenfieldR F Bergstrom
Jan 11, 2000·Clinical Pharmacokinetics·S Kudo, T Ishizaki
Feb 9, 2000·Cancer Chemotherapy and Pharmacology·C MassariG Bastian
Jul 8, 2000·Clinical Pharmacokinetics·C J TimmerL P Delbressine
Aug 25, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·P T ThyrumC Yeh
Feb 24, 2001·European Journal of Clinical Pharmacology·O SpigsetR Dahlqvist
Jun 26, 2002·Kidney International·Antonio A LopesDialysis Outcomes and Practice Patterns Study (DOPPS)
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hiroshi HayashiKoichi Otani
Mar 5, 2003·Journal of Pain and Symptom Management·Mellar P DavisSandy Taylor
May 2, 2003·Psychosomatics·Muhammad N MomenPeter F Buckley
May 14, 2003·Pharmacotherapy·Roy R ReevesJohn J Beddingfield
Jun 27, 2003·Journal of Clinical Psychopharmacology·Isao FukunishiTateki Kitaoka
Mar 11, 2004·Psychiatry and Clinical Neurosciences·Toshiko KamoYasuhiko Maebashi
Jun 18, 2004·Journal of Korean Medical Science·Sang-Kyu LeeBong-Ki Son
Aug 5, 2004·The Journal of Clinical Psychiatry·Steven P James, Wallace B Mendelson
Aug 5, 2004·Nephron. Clinical Practice·Simon P R WorrallSoraya Dhillon
Jan 18, 2005·The American Journal of the Medical Sciences·Ja-Ryong KooBong-Ki Son
Jan 31, 2006·The American Journal of Medicine·Victor L Serebruany
Jul 4, 2006·General Hospital Psychiatry·Rebecca A DrayerBruce L Rollman
Dec 13, 2006·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Adekola O Alao, Lindsay Moskowitz
Feb 8, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·George R BailieEric W Young
Mar 6, 2007·British Journal of Clinical Pharmacology·Miia TurpeinenKari Laine
Sep 14, 2007·Kidney International·W C WinkelmayerP S Wang
Apr 9, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Toyotaka NishioKeiichi Kawai
Jul 10, 2008·Clinical Pharmacokinetics·Suresh MallikaarjunSteven L Bramer
Jul 17, 2008·Nature Clinical Practice. Nephrology·Yolanda E Bogaert, Michel Chonchol
Dec 11, 2008·Pharmacopsychiatry·P M SchlotterbeckD Leube
Apr 14, 2009·Therapeutic Drug Monitoring·Aude JacobChristian Funck-Brentano
Jul 25, 2009·Clinical Pharmacology and Therapeutics·D C Brater
Oct 22, 2009·Clinical Pharmacology and Therapeutics·W J SpruillH H Cobb
Jan 16, 2010·Journal of Clinical Psychopharmacology·Albert BatallaEduard Parellada
Jun 26, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Nian-Sheng Tzeng, Chien-Ping Chiang
Nov 13, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Ahraaz WyneRita S Suri
Dec 24, 2010·International Journal of Clinical Pharmacology and Therapeutics·A I NicholsJ Paul
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Andrea FagioliniFrancesco Casamassima
Jan 25, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Giuseppe LippiGiovanni Targher
Jun 10, 2011·Clinical Pharmacokinetics·Pierre PeetersRik de Greef
Jul 14, 2011·General Hospital Psychiatry·Chia-Ta ChanLih-Chih Jou
Dec 14, 2011·European Journal of Clinical Pharmacology·Hadi MolanaeiLeif Bertilsson
Jan 26, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Eduardo LacsonFredric O Finkelstein
Apr 12, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Ea Wha KangMark Unruh
Aug 4, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Evi V NaglerCarmine Zoccali
Sep 22, 2012·European Journal of Clinical Pharmacology·M J Cooke, W S Waring
Nov 5, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Farhat FarrokhiSarbjit Vanita Jassal
Nov 22, 2013·The Annals of Pharmacotherapy·Kylee A Funk, Jolene R Bostwick
Sep 12, 2014·BMJ : British Medical Journal·Sophie Billioti de GageBernard Bégaud


Dec 7, 2018·Hemodialysis International·Taryn BlahaRupesh Raina
Dec 12, 2020·Journal of Palliative Medicine·Yara MoustafaMaisha T Robinson

Related Concepts

Diagnosis, Psychiatric
Kidney Failure, Chronic
Antipsychotic Effect
Selective Serotonin Reuptake Inhibitors
Mental Disorders
Kidney Failure, Chronic
Drug Kinetics
Psychotropic Drugs

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.